AGLE RSI Chart
Last 7 days
14.0%
Last 30 days
51.4%
Last 90 days
158.0%
Trailing 12 Months
122.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 1.2M | 1.2M | 1.1M | 886.0K |
2022 | 20.1M | 7.0M | 5.8M | 2.3M |
2021 | 5.5M | 9.9M | 14.3M | 18.7M |
2020 | 1.5M | 1.7M | 1.1M | 0 |
2019 | 0 | 3.0M | 1.2M | 0 |
2018 | 5.7M | 6.6M | 5.4M | 3.9M |
2017 | 4.8M | 4.9M | 5.0M | 5.2M |
2016 | 6.9M | 4.9M | 5.0M | 4.6M |
2015 | 0 | 0 | 0 | 6.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Nov 24, 2023 | fairmount funds management llc | acquired | - | - | 3,435,480 | - |
Nov 24, 2023 | turtle cameron | acquired | - | - | 723,440 | chief executive officer |
Aug 25, 2022 | souza marcio | bought | 50,472 | 0.5608 | 90,000 | - |
Jun 08, 2022 | hanley jr. michael conick | bought | 20,022 | 0.71 | 28,200 | chief commercial officer |
Mar 16, 2022 | quinn anthony g. | bought | 187,705 | 2.344 | 80,079 | president & ceo |
Mar 15, 2022 | quinn anthony g. | bought | 78,942 | 1.8611 | 42,417 | president & ceo |
Mar 14, 2022 | quinn anthony g. | bought | 130,221 | 1.93 | 67,472 | president & ceo |
Mar 11, 2022 | quinn anthony g. | bought | 71,779 | 2.064 | 34,777 | president & ceo |
Mar 11, 2022 | alspaugh jonathan | bought | 156,000 | 2.08 | 75,000 | chief financial officer |
Dec 13, 2021 | shanafelt armen | bought | 53,600 | 3.65 | 14,685 | - |
Which funds bought or sold AGLE recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 10, 2024 | CITIGROUP INC | added | 208 | 982,952 | 1,204,540 | -% |
May 10, 2024 | CREDIT SUISSE AG/ | new | - | 836,585 | 836,585 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 9,647 | 84,544 | 85,039 | -% |
May 10, 2024 | OSAIC HOLDINGS, INC. | reduced | -70.67 | -2,941 | 3,147 | -% |
May 10, 2024 | BlackRock Inc. | added | 2,716 | 20,690,000 | 21,115,300 | -% |
May 10, 2024 | VANGUARD GROUP INC | added | 1,160 | 18,009,200 | 18,858,100 | -% |
May 10, 2024 | JPMORGAN CHASE & CO | reduced | -73.17 | -465 | 417 | -% |
May 10, 2024 | ACADIAN ASSET MANAGEMENT LLC | sold off | -100 | -25,000 | - | -% |
May 09, 2024 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | new | - | 568,950 | 568,950 | -% |
May 08, 2024 | TD Asset Management Inc | new | - | 2,312,520 | 2,312,520 | -% |
Unveiling Aeglea BioTherapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Aeglea BioTherapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.2B | 6.8B | -8.07 | 7.03 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.0B | 2.0B | -57.12 | 9.47 | ||||
BMRN | 15.3B | 2.5B | 74.39 | 6.18 | ||||
INCY | 12.9B | 3.8B | 17.35 | 3.43 | ||||
MID-CAP | ||||||||
BBIO | 5.3B | 107.9M | -9.76 | 48.09 | ||||
APLS | 5.2B | 524.1M | -12.51 | 9.96 | ||||
AXSM | 3.6B | 251.0M | -12.12 | 14.31 | ||||
ARWR | 2.7B | 240.7M | -5.82 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.5K | 3.08 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.44 | 4.66 | ||||
NVAX | 1.8B | 996.6M | -4.62 | 1.85 | ||||
CRBP | 458.7M | 881.7K | -13.59 | 481.06 | ||||
INO | 265.7M | 4.9M | -1.97 | 54.6 | ||||
IBIO | 6.3M | 2.1M | -0.23 | 2.14 |
Aeglea BioTherapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q3 | 2019Q2 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | - | - | - | - | 688,000 | 198,000 | 168,000 | 174,000 | 625,000 | 1,362,000 | 3,644,000 | 1,399,000 | 13,696,000 | 6,892,000 | 88,000 | 161,000 | 300,000 | 585,000 | 619,000 | 12,000 | - | 2,378,000 |
Operating Expenses | 4.1% | 47,774,000 | 45,914,000 | 18,337,000 | 159,934,000 | 19,004,000 | 19,330,000 | 18,929,000 | 23,048,000 | 25,803,000 | 24,086,000 | 21,692,000 | 20,401,000 | 18,209,000 | 18,123,000 | 21,560,000 | 19,022,000 | 22,146,000 | 18,622,000 | 15,305,000 | 12,243,000 | 12,048,000 |
S&GA Expenses | -100.0% | - | 14,072,000 | 8,584,000 | 12,062,000 | 5,228,000 | 5,079,000 | 6,952,000 | 7,675,000 | 8,825,000 | 7,304,000 | 6,839,000 | 6,822,000 | 6,354,000 | 5,672,000 | 4,691,000 | 4,460,000 | 4,307,000 | 3,816,000 | 3,507,000 | 3,314,000 | 2,926,000 |
R&D Expenses | - | - | - | - | - | 13,776,000 | 14,251,000 | 11,977,000 | 15,373,000 | 16,978,000 | 16,782,000 | 14,853,000 | 13,579,000 | 11,855,000 | 12,451,000 | 16,869,000 | 14,562,000 | 17,839,000 | 14,806,000 | 11,798,000 | 8,929,000 | 9,122,000 |
EBITDA Margin | -7.6% | -410 | -381 | -278 | -220 | -65.61 | -35.38 | -14.47 | -12.21 | -3.50 | -3.66 | -4.62 | -6.80 | - | - | - | - | - | - | - | - | - |
Income Taxes | - | 32,000 | - | 3,000 | 7,000 | -36,000 | 51,000 | -209,000 | 9,000 | - | 23,000 | 26,000 | 92,000 | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 30.6% | -43,825,000 | -63,180,000 | -40,104,000 | -217,074,000 | -18,458,000 | -18,771,000 | -18,443,000 | -22,314,000 | -24,436,000 | -20,423,000 | -20,281,000 | -6,738,000 | - | -18,033,000 | -21,418,000 | - | - | - | - | - | - |
EBT Margin | -7.5% | -411 | -382 | -279 | -222 | -66.94 | -36.05 | -14.75 | -12.44 | -3.58 | -3.74 | -4.73 | -6.93 | - | - | - | - | - | - | - | - | - |
Net Income | 30.6% | -43,857,000 | -63,180,000 | -40,107,000 | -217,081,000 | -18,422,000 | -18,822,000 | -18,234,000 | -22,323,000 | -24,436,000 | -20,446,000 | -20,307,000 | -6,830,000 | -18,218,000 | -18,033,000 | -21,418,000 | -18,728,000 | -21,573,000 | -18,019,000 | -14,898,000 | -11,917,000 | -9,414,000 |
Net Income Margin | -7.5% | -411 | -382 | -279 | -221 | -66.78 | -35.99 | -14.72 | -12.45 | -3.58 | -3.51 | -4.75 | -6.62 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 8.0% | -28,542,000 | -31,036,000 | -34,597,000 | -16,643,000 | -17,634,000 | -18,140,000 | -15,069,000 | -20,673,000 | -26,300,000 | -19,268,000 | -17,093,000 | 2,052,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 42.6% | 488 | 342 | 207 | 244 | 52.00 | 71.00 | 92.00 | 107 | 83.00 | 110 | 129 | 147 | 164 | 162 | 156 | 173 | 65.00 | 83.00 | 100 | 117 | 129 |
Current Assets | 42.7% | 487 | 342 | 206 | 240 | 44.00 | 62.00 | 82.00 | 97.00 | 73.00 | 99.00 | 118 | 134 | 151 | 150 | 144 | 162 | 54.00 | 75.00 | 93.00 | 110 | 127 |
Cash Equivalents | 20.6% | 228 | 189 | 91.00 | 3.00 | 35.00 | 35.00 | 41.00 | 37.00 | 15.00 | 17.00 | 25.00 | 35.00 | 80.00 | 92.00 | 54.00 | 66.00 | 13.00 | 19.00 | 25.00 | 25.00 | 86.00 |
Net PPE | - | - | - | - | - | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 6.00 | 5.00 | 5.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 |
Liabilities | 11.8% | 82.00 | 73.00 | 66.00 | 254 | 19.00 | 21.00 | 24.00 | 23.00 | 22.00 | 26.00 | 27.00 | 28.00 | 40.00 | 22.00 | 19.00 | 21.00 | 22.00 | 23.00 | 20.00 | 18.00 | 12.00 |
Current Liabilities | 33.9% | 43.00 | 32.00 | 45.00 | 232 | 13.00 | 15.00 | 18.00 | 16.00 | 16.00 | 20.00 | 20.00 | 21.00 | 32.00 | 16.00 | 14.00 | 16.00 | 17.00 | 18.00 | 15.00 | 13.00 | 12.00 |
Shareholder's Equity | -17.3% | 152 | 184 | - | - | 34.00 | 50.00 | 68.00 | 84.00 | 62.00 | 84.00 | 102 | 119 | 124 | 140 | 136 | 152 | 43.00 | 60.00 | 80.00 | 100 | 116 |
Retained Earnings | -5.7% | -808 | -764 | -701 | -661 | -444 | -425 | -406 | -388 | -366 | -341 | -321 | -301 | -294 | -276 | -253 | -235 | -213 | -195 | -173 | -152 | -134 |
Additional Paid-In Capital | 1.7% | 776 | 763 | 456 | 454 | 478 | 476 | 475 | 473 | 428 | 426 | 423 | 420 | 418 | 416 | 390 | 387 | 257 | 255 | 253 | 252 | 250 |
Shares Outstanding | 1.6% | 37.00 | 36.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 26.00 | - | - | - | 30.00 | - | - | - | 337 | - | - | - | 386 | - | - | - | 178 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 8.0% | -28,542 | -31,036 | -34,597 | -16,643 | -17,634 | -18,140 | -15,068 | -20,673 | -26,263 | -19,268 | -17,000 | 2,082 | -19,530 | -17,132 | -17,536 | -19,413 | -21,694 | -16,294 | -17,208 | -16,383 | -15,807 |
Share Based Compensation | -20.1% | 13,800 | 17,270 | 4,785 | 1,911 | 1,709 | 1,427 | 1,566 | 2,017 | 2,101 | 2,094 | 2,107 | 2,080 | 1,757 | 1,612 | 1,696 | 1,600 | 1,348 | 1,184 | 1,366 | 1,245 | 1,081 |
Cashflow From Investing | -197.6% | -104,963 | -35,272 | -97,631 | 6,760 | 17,750 | 14,000 | 16,499 | 750 | 25,759 | 9,663 | 5,777 | -47,359 | 9,300 | 28,620 | 5,784 | -56,761 | 14,753 | 10,326 | 16,012 | -42,013 | 13,936 |
Cashflow From Financing | 5.2% | 172,165 | 163,606 | -12,531 | 209,992 | 10.00 | -8.00 | -130 | 42,804 | 12.00 | 80.00 | 1,143 | -192 | 362 | 24,679 | 258 | 129,293 | 282 | 676 | 311 | -319 | 65,055 |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||||
---|---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |||
Revenue: | |||||
Total revenue | $ 886 | $ 2,329 | $ 18,739 | ||
Operating expenses: | |||||
Research and development | [1] | 89,504 | 58,579 | 57,069 | |
General and administrative | 39,946 | 28,531 | 27,319 | ||
Acquired in-process research and development | 130,188 | 0 | 0 | ||
Gain on sale of in-process research and development asset | (16,449) | 0 | 0 | ||
Total operating expenses | 243,189 | 87,110 | 84,388 | ||
Loss from operations | (242,303) | (84,781) | (65,649) | ||
Other (expense) income: | |||||
Interest income | 6,147 | 837 | 111 | ||
Other expense, net | (19,130) | (7) | (122) | ||
Total other (expense) income | (96,513) | 830 | (11) | ||
Loss before income tax expense | (338,816) | (83,951) | (65,660) | ||
Income tax benefit (expense) | 26 | 136 | (141) | ||
Net loss | $ (338,790) | $ (83,815) | $ (65,801) | ||
Net loss per share, basic (in dollars per share) | $ (49.12) | $ (24.86) | $ (25.02) | ||
Net loss per share, diluted (in dollars per share) | $ (49.12) | $ (24.86) | $ (25.02) | ||
Weighted-average common shares outstanding, basic (in shares) | 6,897,065 | 3,371,231 | 2,629,784 | ||
Weighted-average common shares outstanding, diluted (in shares) | 6,897,065 | 3,371,231 | 2,629,784 | ||
Forward Contract Liability | |||||
Other (expense) income: | |||||
Change in fair value of forward contract liability | $ (83,530) | $ 0 | $ 0 | ||
License | |||||
Revenue: | |||||
Total revenue | 0 | 0 | 12,000 | ||
Development fee and royalty | |||||
Revenue: | |||||
Total revenue | $ 886 | $ 2,329 | $ 6,739 | ||
|
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
CURRENT ASSETS | ||
Cash and cash equivalents | $ 188,893 | $ 34,863 |
Marketable securities | 150,384 | 20,848 |
Development receivables | 0 | 375 |
Prepaid expenses and other current assets | 2,251 | 6,172 |
Total current assets | 341,528 | 62,258 |
Restricted cash | 322 | 1,553 |
Property and equipment, net | 0 | 3,220 |
Operating lease right-of-use assets | 0 | 3,430 |
Other non-current assets | 9 | 683 |
TOTAL ASSETS | 341,859 | 71,144 |
CURRENT LIABILITIES | ||
Accounts payable | 896 | 677 |
CVR liability | 1,390 | 0 |
Operating lease liabilities | 0 | 625 |
Deferred revenue | 0 | 517 |
Accrued and other current liabilities | 13,108 | 12,837 |
Related party accounts payable and other current liabilities | 16,584 | 0 |
Total current liabilities | 31,978 | 14,656 |
Non-current CVR liability | 41,310 | 0 |
Non-current operating lease liabilities | 0 | 4,004 |
Deferred revenue, net of current portion | 0 | 2,179 |
TOTAL LIABILITIES | 73,288 | 20,839 |
Commitments and Contingencies (Note 9) | ||
Series B non-voting convertible preferred stock, $0.0001 par value; 150,000 and no shares authorized as of December 31, 2023 and December 31, 2022, respectively; 150,000 and no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively. | 84,555 | 0 |
STOCKHOLDERS’ EQUITY | ||
Common stock, $0.0001 par value; 400,000,000 and 20,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 36,057,109 shares and 2,614,014 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively. | 10 | 6 |
Additional paid-in capital | 763,191 | 475,971 |
Accumulated other comprehensive income (loss) | 302 | (48) |
Accumulated deficit | (764,414) | (425,624) |
TOTAL STOCKHOLDERS’ EQUITY | 184,016 | 50,305 |
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | 341,859 | 71,144 |
Series A Non-Voting Convertible Preferred Stock | ||
STOCKHOLDERS’ EQUITY | ||
Preferred stock | 184,927 | 0 |
Preferred Stock | ||
STOCKHOLDERS’ EQUITY | ||
Preferred stock | $ 0 | $ 0 |